Zenas BioPharma, Inc. business relationships
Companies named in Zenas BioPharma, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name Zenas BioPharma, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Zenas BioPharma, Inc.’s annual report 11
“...on-royalty income attributable to obexelimab products payable to us or any of our affiliates by its licensees (other than certain milestone payments payable by Bristol-Myers Squibb) pursuant to out-licenses and allocated to countries other than the U.S., the United Kingdom and in the European Union.” SEC filing
“License Agreement with Bristol-Myers Squibb” SEC filing
“License and Collaboration Agreement with Bristol-Myers Squibb” SEC filing
“...ted Kingdom, and in the European Union by its licensees pursuant to out-licenses less royalty payments payable by us to Xencor Inc. and (iv) 25% of non-royalty income attributable to obexelimab products payable to us or any of our affiliates by its licensees (other than certain milestone payments pa...” SEC filing
“License Agreements with Xencor, Inc.” SEC filing
“In September 2025, we entered into the Royalty Purchase Agreement with Royalty Pharma, pursuant to which Royalty Pharma purchased the right to receive, for each calendar quarter, (i) 5.5% of net sales of obexelimab products sold by us and our affiliates worldwide, (ii) 5.5% of net sales of obexelima...” SEC filing
“...nt contains covenants that impose on us certain obligations, including with respect to royalty payments, advancement of our obexelimab program and reporting of clinical, regulatory and commercial updates to Royalty Pharma and includes restrictions on intellectual property transfers and out-licenses.” SEC filing
“...ting activities for the year ended December 31, 2025 was $172.3 million, and was primarily due to our net loss of $377.7 million, which included non-cash charges principally related to the InnoCare license agreement, stock-based compensation and interest charges on our agreement with Royalty Pharma.” SEC filing
“License Agreement with Zai Lab (Hong Kong) Limited” SEC filing
“...Co., Limited ("Tenacia"), license agreement with Zai Lab (Hong Kong) Limited ("Zai") and a royalty purchase agreement with Royalty Pharma Investments ("Royalty Pharma") (please see Note 7, License and Collaboration Revenue and Note 9, Royalty Obligation, to these consolidated financial statements).” SEC filing
“License Agreement with Viridian Therapeutics, Inc.” SEC filing
Companies whose annual reports name Zenas BioPharma, Inc. 6
“In January 2025, the Company entered into a license agreement with Zenas BioPharma (HK) Limited ("Zenas"), pursuant to which the Company obtained a license under certain patents and know-how of Zenas to develop and commercialize products containing a differentiated humanized monoclonal antibody targ...” SEC filing
“As described below, we licensed the right to develop, manufacture and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China to Zenas BioPharma (Cayman) Limited (now Zenas BioPharma, Inc., their successor in interest, "Zenas BioPharma").” SEC filing
“License Agreement with Zenas BioPharma” SEC filing
“Collaboration revenue - related parties for the years ended December 31, 2025 and 2024 was attributable to our collaboration agreement with Zenas BioPharma and the Side Agreement and MTA with Zai Lab.” SEC filing
“In May 2022, we entered into a manufacturing development and supply agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical drug product for development purposes.” SEC filing
“On October 21, 2024, Zenas assigned the Zenas License Agreement to its affiliated entity, Zenas BioPharma (HK) Limited ("Zenas HK").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.